C9Orf72 Hexanucleotide Repeat Expansion is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and Frontotemporal Dementia (FTD). This GGGGCC repeat expansion in the non-coding region of the C9orf72 gene leads to disease through three main molecular mechanisms: loss of C9orf72 protein function, RNA toxicity from expanded repeat transcripts, and dipeptide repeat protein (DPR) toxicity from anomalous translation.
The expansion was first identified in 2011 and is found in approximately 40% of familial ALS cases, 25% of familial FTD cases, and a significant portion of patients with ALS-FTD spectrum disorders.12
- Normal: 2-8 GGGGCC repeats
- Intermediate: 20-30 repeats (reduced penetrance)
- Pathogenic: >30 repeats (fully penetrant)
The expansion occurs in the first intron of the C9orf72 gene on chromosome 9p21.2. Normal individuals have 2-8 repeats, while affected individuals typically have hundreds to thousands of repeats.3
The expansion exhibits autosomal dominant inheritance with high but incomplete penetrance. Age of onset typically ranges from 40-70 years, with significant variability even within families carrying the same repeat size.4
The repeat expansion reduces C9orf72 gene expression through:
- DNA hypermethylation at the repeat expansion site
- Transcriptional silencing
- Haploinsufficiency of the C9orf72 protein
The normal C9orf72 protein is involved in:
- Endolysosomal trafficking
- Autophagy regulation
- Nuclear transport
- Synaptic function
Loss of C9orf72 function disrupts these critical cellular processes.5
Expanded repeat transcripts form toxic RNA structures that:
- Sequester RNA-binding proteins (RBPs)
- Disrupt normal RNA splicing
- Cause nucleolar stress
- Impair nucleocytoplasmic transport
The repeats form G-quadruplex structures that bind and sequester multiple RNA-binding proteins including hnRNPs, nucleolin, and others.6
Through repeat-associated non-ATG (RAN) translation, the expansion produces five toxic dipeptide repeat proteins:
- Poly-GA (glycine-alanine)
- Poly-GP (glycine-proline)
- Poly-GR (glycine-arginine)
- Poly-PR (proline-arginine)
- Poly-PA (proline-alanine)
These DPRs accumulate in neuronal inclusions and cause:
- Proteasome inhibition
- Stress granule formation
- Nucleocytoplasmic transport disruption
- Mitochondrial dysfunction
- Synaptic impairment
The poly-GR and poly-PR DPRs are particularly toxic to neurons.78
C9orf72-associated ALS typically presents with:
- Limb-onset weakness (most common)
- Bulbar onset (less common)
- Rapid progression
- Combined upper and lower motor neuron signs
The behavioral variant FTD (bvFTD) presentation includes:
- Disinhibition
- Apathy
- Loss of social conduct
- Cognitive impairment
Many patients present with overlapping features:
- Motor Neuron Disease with cognitive decline
- Language-variant FTD with motor features
- Progressive aphasia with ALS
- Motor cortex
- Spinal cord anterior horns
- Frontal and temporal cortex
- Basal ganglia
- Hippocampus
- Cerebellum
- TDP-43 positive inclusions (most common)
- p62 positive inclusions
- DPR inclusions (C9orf72-specific)
- Neuronal loss and gliosis
- Mean: 55-60 years
- Range: 30-80 years
- Earlier onset in some families
- ALS: 2-4 years median survival
- FTD: 6-11 years median survival
- ALS-FTD: Variable, often 3-5 years
- Up to 50% of C9orf72-ALS patients develop cognitive impairment
- Frontotemporal Dementia in 15-30%
- Executive dysfunction most common
- PCR-based repeat expansion detection
- Southern blot for repeat sizing
- Available clinically for at-risk individuals
- Elevated neurofilament light chain (NfL) in CSF and blood
- Reduced C9orf72 expression in blood
- DPR proteins in CSF (research use)
- Awaredness of family history critical
- Standard ALS/FTD diagnostic criteria apply
- Antisense oligonucleotides (ASOs) targeting C9orf72 transcripts
- CRISPR-based approaches (preclinical)
- Gene silencing strategies
- Nucleolin-targeted compounds
- G-quadruplex stabilizers
- DPR-targeted agents
- Riluzole (modest survival benefit)
- Edaravone (selected patients)
- Multidisciplinary care
- Speech, physical, occupational therapy
The study of C9Orf72 Hexanucleotide Repeat Expansion has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- NEK1 variants constitute an additional genetic determinant in an ALS patient with a C9orf72 repeat expansion. Neurology, 2016.
- C9orf72 and the genetics of ALS: a rekindled therapeutic target. Nature Reviews Neurology, 2013.
- Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron, 2011.
- C9orf72-mediated ALS and FTD: common pathways, divergent phenotypes, and therapeutic targets. Journal of Molecular Neuroscience, 2014.
- C9orf72 is required for proper neuronal and glial function in the mammalian brain. Neuron, 2013.
- RNA toxicity from the ALS/FTD C9orf72 expansion is mitigated by antisense oligonucleotides. Neuron, 2016.
- The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature, 2015.
- Unconventional translation of C9ORF72 GGGGCC expansions generates dipeptide repeat proteins that are toxic in Drosophila models of FTD/ALS. Acta Neuropathologica Communications, 2019.
- Dipeptide repeat proteins from the C9orf72 hexanucleotide expansion are highly immunogenic and induce neurodegenerative pathology. Acta Neuropathologica, 2016.
- Antisense oligonucleotides targeting C9orf72 RNAs improve behavior and neuropathology in a mouse model. Journal of Clinical Investigation, 2018.
- Page created: 2026-03-01
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
11 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 33%